TOP TEN perturbations for 39311_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39311_at
Selected probe(set): 204437_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39311_at (204437_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO endometrial cancer study 1 (malignant mixed Mullerian tumor; metastatic)
Relative Expression (log2-ratio):6.733329Number of Samples:2 / 5
| Experimental | expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the endometrium. | |
| Control | expO endometrial cancer study 1 (malignant mixed Mullerian tumor; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary malignant mixed Mullerian tumor of the endometrium. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Relative Expression (log2-ratio):5.794471Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. |
expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO endometrial cancer study 1 (endometrioid carcinoma; metastatic)
Relative Expression (log2-ratio):5.7276506Number of Samples:2 / 20
| Experimental | expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the endometrium. | |
| Control | expO endometrial cancer study 1 (endometrioid carcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the endometrium. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):5.655658Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (serous cystadenocarcinoma)
Relative Expression (log2-ratio):-5.56987Number of Samples:44 / 71
| Experimental | breast cancer study 40 (metastase; ovary) |
| Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer. | |
| Control | ovarian tumor study 28 (serous cystadenocarcinoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with malignant serous cystadenocarcinoma. |
expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (neuroendocrine carcinoma; primary)
Relative Expression (log2-ratio):5.4314957Number of Samples:2 / 6
| Experimental | expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS). | |
| Control | expO lung cancer study 1 (neuroendocrine carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):5.3780966Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
expO ovary cancer study 1 (mucinous adenocarcinoma; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)
Relative Expression (log2-ratio):-5.3746758Number of Samples:6 / 2
| Experimental | expO ovary cancer study 1 (mucinous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma. | |
| Control | expO ovary cancer study 1 (carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS). |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):5.3446016Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
nephroblastoma study 2 / normal kidney tissue (adult)
Relative Expression (log2-ratio):-5.213621Number of Samples:4 / 3
| Experimental | nephroblastoma study 2 |
| Tumor tissue samples from the kidney of patients with Wilms’ tumor. | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |